What trends will be with us in the field of clinical research in the coming months?
Remote monitoring of clinical trials, patient-centric processes or the real use of Real World Data will certainly accompany us in the coming months.
1. Decentralization of Clinical Research
The process started in 2020, when the Covid-19 pandemic was taking its first steps, seems to be taking firm shape in 2022. These are no longer plans or tentative attempts to conduct clinical trials in a remote/hybrid manner, but concrete implementations and steps taken by more centers.
Regulatory clarification, the emergence of professional software (such as MCR Clinic), combined with the first successes of sites implementing remote monitoring of clinical trials, promise further development of the trend.*
2. Digitization of the supply chain
In the coming months, we can also expect to see the digitization of the supply chain in the clinical trial sector. This means the development of fully integrated process management tools that minimize manual work.
Digitization of the supply chain will include real-time tracking of drug status and location, among other things, which is expected to increase efficiency and safety.
3. Players from outside the sector
The year 2022 is predicted to bring the involvement of large companies outside of healthcare: Microsoft, Google, Amazon or Apple. The entry of these players into the clinical trials market will have a huge impact on available technologies and infrastructure development.
4. Access to Real-World Data
Changing regulations combined with advances in technology mean that in 2022 we will see a revolution in data collection and use.
Wider use of RWD will allow for a more targeted group of patients (including recruitment of patients with rare diseases), but will also allow for better control over the entire process.
5. Patient at the center of research
The consequence of these changes, including the trends mentioned above, is to put the patient at the center of the clinical trial process. It is patients who stand to benefit the most from the changes taking place: they will receive better care, easier contact with their doctor, better selected drugs and faster diagnosis.**
***
Sources:
* https://www.clinicalleader.com/doc/trends-to-watch-in-rwd-dcts-and-cell-gene-trials-0001
**https://www.obviohealth.com/news/4-clinical-trial-trends-for-2022-better-patient-data-with-less-patient-effort
***
